198 related articles for article (PubMed ID: 35670342)
41. Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: synthetic approaches and multifarious applications.
Khan I; Ibrar A; Abbas N; Saeed A
Eur J Med Chem; 2014 Apr; 76():193-244. PubMed ID: 24583357
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in the chemistry and biology of pyridopyrimidines.
Buron F; Mérour JY; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2015 May; 95():76-95. PubMed ID: 25794791
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic significance of quinolines: a patent review (2013-2015).
Hussaini SM
Expert Opin Ther Pat; 2016 Oct; 26(10):1201-21. PubMed ID: 27458877
[TBL] [Abstract][Full Text] [Related]
44. Anti-cancer therapeutic potential of quinazoline based small molecules via global upregulation of miRNAs.
Nahar S; Bose D; Kumar Panja S; Saha S; Maiti S
Chem Commun (Camb); 2014 May; 50(35):4639-42. PubMed ID: 24671295
[TBL] [Abstract][Full Text] [Related]
45. A Comprehensive Review on Recent advances in Synthesis & Pharmacotherapeutic potential of Benzothiazoles.
Seth S
Antiinflamm Antiallergy Agents Med Chem; 2015; 14(2):98-112. PubMed ID: 26017385
[TBL] [Abstract][Full Text] [Related]
46. Synthesis, antimicrobial evaluation, and docking studies of novel 4-substituted quinazoline derivatives as DNA-gyrase inhibitors.
Boyapati S; Kulandaivelu U; Sangu S; Vanga MR
Arch Pharm (Weinheim); 2010 Oct; 343(10):570-6. PubMed ID: 20941729
[TBL] [Abstract][Full Text] [Related]
47. The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Li Y; Xiao J; Zhang Q; Yu W; Liu M; Guo Y; He J; Liu Y
Bioorg Med Chem; 2019 Feb; 27(3):568-577. PubMed ID: 30600149
[TBL] [Abstract][Full Text] [Related]
48. 2-Pyrazolines as Biologically Active and Fluorescent Agents, An Overview.
Singh P; Singh J; Pant GJ; Rawat MSM
Anticancer Agents Med Chem; 2018; 18(10):1366-1385. PubMed ID: 29532762
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.
Haghighijoo Z; Zamani L; Moosavi F; Emami S
Eur J Med Chem; 2022 Jan; 227():113949. PubMed ID: 34742016
[TBL] [Abstract][Full Text] [Related]
50. Recent contributions of quinolines to antimalarial and anticancer drug discovery research.
Van de Walle T; Cools L; Mangelinckx S; D'hooghe M
Eur J Med Chem; 2021 Dec; 226():113865. PubMed ID: 34655985
[TBL] [Abstract][Full Text] [Related]
51. Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives.
Kumari A; Singh RK
Bioorg Chem; 2019 Aug; 89():103021. PubMed ID: 31176854
[TBL] [Abstract][Full Text] [Related]
52. Synthesis of Azoloquinazolines and Substituted Benzothiazepine as Antimicrobial Agents.
Kassem AF; Alshehrei F; Abbas EMH; Farghaly TA
Mini Rev Med Chem; 2020; 20(5):418-429. PubMed ID: 31161988
[TBL] [Abstract][Full Text] [Related]
53. Pharmacotherapeutics Applications and Chemistry of Chalcone Derivatives.
Dhaliwal JS; Moshawih S; Goh KW; Loy MJ; Hossain MS; Hermansyah A; Kotra V; Kifli N; Goh HP; Dhaliwal SKS; Yassin H; Ming LC
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296655
[TBL] [Abstract][Full Text] [Related]
54. Antimicrobial and Cytotoxic Evaluation of New Quinazoline Derivatives.
Turan-Zitouni G; Yurttaş L; Saka G; Cantürk Z; Gencer HK; Baysal M; Kaplancιkh ZA
Nat Prod Commun; 2016 Nov; 11(11):1645-1648. PubMed ID: 30475497
[TBL] [Abstract][Full Text] [Related]
55. Isatin Hybrids and Their Pharmacological Investigations.
Varpe BD; Kulkarni AA; Jadhav SB; Mali AS; Jadhav SY
Mini Rev Med Chem; 2021; 21(10):1182-1225. PubMed ID: 33302835
[TBL] [Abstract][Full Text] [Related]
56. Mono and bis-6-arylbenzimidazo[1,2-c]quinazolines: a new class of antimicrobial agents.
Rohini R; Shanker K; Reddy PM; Ho YP; Ravinder V
Eur J Med Chem; 2009 Aug; 44(8):3330-9. PubMed ID: 19371978
[TBL] [Abstract][Full Text] [Related]
57. Synthesis of novel 4,6-disubstituted quinazoline derivatives, their anti-inflammatory and anti-cancer activity (cytotoxic) against U937 leukemia cell lines.
Chandrika PM; Yakaiah T; Rao AR; Narsaiah B; Reddy NC; Sridhar V; Rao JV
Eur J Med Chem; 2008 Apr; 43(4):846-52. PubMed ID: 17689837
[TBL] [Abstract][Full Text] [Related]
58. Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
Yang SM; Yoshioka M; Strovel JW; Urban DJ; Hu X; Hall MD; Jadhav A; Maloney DJ
Bioorg Med Chem Lett; 2019 May; 29(10):1220-1226. PubMed ID: 30905542
[TBL] [Abstract][Full Text] [Related]
59. Novel substituted hydrazono indolo[2,1-b]quinazoline-6,12-dione analogues as cytostatic agents: Synthesis, crystal structure, biological evaluation and molecular docking studies.
Guda R; Narsimha S; Babu R; Muthadi S; Lingabathula H; Palabindela R; Yellu NR; Kumar G; Kasula M
Bioorg Med Chem Lett; 2016 Nov; 26(22):5517-5523. PubMed ID: 27769618
[TBL] [Abstract][Full Text] [Related]
60. A comprehensive insight on the biological potential of embelin and its derivatives.
Basha NJ; Basavarajaiah SM; Baskaran S; Kumar P
Nat Prod Res; 2022 Jun; 36(12):3054-3068. PubMed ID: 34304655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
